Lung Health: Bristol Myers Partners with Microsoft for Early Disease Detection with AI

Lung health has interested Bristol Myers Squibb in terms of using artificial intelligence for early detection of diseases of this organ. Among the partners in implementing the idea is Microsoft. The agreement has already been concluded. The priority is cancer.

As part of the collaboration, the collaboration will introduce FDA-approved artificial intelligence algorithms for radiology through the Microsoft Precision Imaging Network, xrust said. It analyzes X-rays and CT scans to detect lung diseases and is used by hospitals in the United States.

Bristol Myers said the tools could help doctors identify hard-to-detect lung nodules and identify some patients at earlier stages of the disease.

The pharmaceutical company also said one of the key goals of the partnership is to expand access to early diagnosis in medically underserved areas, including rural hospitals and community clinics across the United States.

Microsoft said that by combining Microsoft's scalable radiology solutions with Bristol's deep expertise in oncology and drug delivery, we have developed a unique AI-powered workflow that helps clinicians quickly and accurately identify patients with non-small cell lung cancer and guide them to optimal treatment regimens and precision therapies.

Pharmaceutical companies are increasingly turning to artificial intelligence to speed up research and development, hoping that new simulation tools and automated laboratories can improve the efficiency of all stages of their manufacturing processes.

Last week, AstraZeneca said it had reached an agreement to acquire Boston-based Modella AI to accelerate research into oncology drugs.

Xrust Lung Health: Bristol Myers Partners with Microsoft for Early Disease Detection with AI